VIFOR PHARMA joins the Rare Disease Action Forum as member

    22 Jul, 2020

    We are proud to welcome Vifor Pharma as the newest member of the Rare Disease Action Forum. We look forward to Vifor’s contribution to the collaborative efforts at the RDAF multi-stakeholder platform which consists of members from industry, patient organizations, healthcare professionals, and research organizations. Together we will continue our efforts to diagnosis, treatment and care for patients with rare diseases in Switzerland.

    Continue reading

    Joint statement on the KVV/OAMal and KLV/OPAS revision

    The RDAF co-signed a joint statement with other stakeholders on the revision of the Health Insurance Ordinance (KVV/OAMal) and Health Benefits Ordinance (KLV/OPAS). The statement highlights the potential negative impacts of the revision, including the following: -...